EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer

Bianca A M H van Veggel iD, Anthonie J van der Wekken, Marthe S Paats, Lizza E L Hendriks, Sayed M S Hashemi, Antonios Daletzakis, Daan van den Broek, Linda J W Bosch, Kim Monkhorst, Egbert F Smit, Adrianus J de Langen

Cancer · 2024

DOI: 10.1002/cncr.35090 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer, 2024. Verfasst von Bianca A M H van Veggel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Boehringer Ingelheim, Merck BV, an affiliate of Merck KGaA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epidermal growth factor receptor ( EGFR ) exon 20 insertion (ex20ins) mutations are the third most common EGFR mutations in patients with non–small cell lung cancer (NSCLC) and are associated with primary resistance to EGFR tyrosine kinase inhibitors (TKIs). There is evidence of activity of combining EGFR TKIs with monoclonal antibodies. This study reports on the efficacy and safety of afatinib in combination with cetuximab.

Methods

In this single‐arm phase 2 trial, patients with advanced NSCLC harboring an EGFR ex20ins mutation were treated with afatinib 40 mg once daily in combination with cetuximab 500 mg/m 2 every 2 weeks. The primary end point was disease control rate (DCR) at 18 weeks of treatment.

Results

Thirty‐seven patients started treatment, with a median age of 65 years (range, 40–80 years), 78% female, and 95% White. The study achieved its primary end point with a DCR of 54% at 18 weeks, an overall response rate (ORR) of 43%, and a 32% confirmed ORR. Best responses were partial ( n = 16), stable ( n = 16), progressive disease ( n = 2), or not evaluable ( n = 3). Median progression‐free survival was 5.5 months (95% CI, 3.7–8.3 months) and median overall survival was 16.8 months (95% CI, 10.7–25.8 months). The most common treatment‐related adverse events (TRAEs) were diarrhea (70%), rash (65%), dry skin (59%), paronychia (54%), and erythema (43%). Grade 3 TRAEs were reported in 54% of all patients.

Conclusions

Combination treatment with afatinib and cetuximab demonstrated antitumor activity with a DCR of 54% at 18 weeks and a 32% confirmed ORR. Toxicity was significant, although manageable, after dose reduction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleAdultMiddle AgedAgedAged, 80 and overMaleAfatinibCetuximabErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsExonsMutationProtein Kinase Inhibitors

Stichwörter der Autor:innen

EGFR exon 20 insertionafatinibcetuximabnon-small cell lung cancer

Substanzen

AfatinibCetuximabErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.
  • Department of Pulmonary Diseases, University of Groningen and University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Pulmonary Diseases, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands.
  • Department of Pulmonary Diseases, Maastricht University Medical Center, Maastricht, the Netherlands.
  • Department of Pulmonary Medicine, Amsterdam University Medical Centers, Vrije Universiteit Medical Center, and Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

ORCID-Profile: Bianca A M H van Veggel

Förderung

  • Boehringer Ingelheim
  • Merck BV, an affiliate of Merck KGaA

Zitieren

APA

van Veggel, B. A. M. H., van der Wekken, A. J., Paats, M. S., Hendriks, L. E. L., Hashemi, S. M. S., Daletzakis, A., van den Broek, D., Bosch, L. J. W., Monkhorst, K., Smit, E. F., & de Langen, A. J. (2024). A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.35090

Vancouver

van Veggel BAMH, van der Wekken AJ, Paats MS, Hendriks LEL, Hashemi SMS, Daletzakis A, et al. A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer. Cancer. 2024. doi:10.1002/cncr.35090

BibTeX
@article{vanVeggel2024,
  author = {van Veggel, Bianca A M H and van der Wekken, Anthonie J and Paats, Marthe S and Hendriks, Lizza E L and Hashemi, Sayed M S and Daletzakis, Antonios and van den Broek, Daan and Bosch, Linda J W and Monkhorst, Kim and Smit, Egbert F and de Langen, Adrianus J},
  title = {A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35090}
}
Kostenlos starten →